TrialLancet (London, England)2023

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.

Fabrice André et al.PubMed ↗Publisher ↗

No numbers read from the abstract.